Giuseppe MichieliEffectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html
#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html
#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html
#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html
The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html
#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html
John E. Bartley, III (D) K7AAY
Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes
In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.
Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub
Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.
The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
The use of fixed dose-combinations of antivirals with different mechanisms of action has proven key in the successful treatment of infections with HIV…
genXcrone (she/her)This meta-analysis of nine studies encompassing 866,066 patients with COVID-19 demonstrated that use of oral antiviral drugs including [paxlovid] and mulnupiravir during the acute phase of SARS-CoV-2 infection was significantly associated with a lower risk of [post covid-19 condition] development.
Learn more from Matthew Cortland:
https://www.patreon.com/posts/good-news-early-105590371